Congestive heart failure with reduced EF: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
Line 8: | Line 8: | ||
<br /> | <br /> | ||
=== Activation of DNA binding | === Activation of DNA binding transcription factors === | ||
=== Protein kinase B signalling === | |||
=== MAPK cascade === | |||
<br /> | <br /> | ||
=== Dysregulation of cellular protein metabolic pathways === | === Dysregulation of cellular protein metabolic pathways === | ||
=== Role of ERK1 and ERK2 pathways === | |||
=== Role of nitric oxide biosynthetic pathway === | === Role of nitric oxide biosynthetic pathway === | ||
=== Smooth muscle cell proliferation === |
Revision as of 19:27, 23 December 2019
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
Heart Failure With Reduced EF
Activation of DNA binding transcription factors
Protein kinase B signalling
MAPK cascade